Ikarovec Secures Global Option to VectorBuilder’s Intravitreal Capsid Technology

Shots: Ikarovec has entered into an exclusive worldwide option agreement for VectorBuilder’s AAV capsid technology to be used with Ikarovec’s IKAR-003 for intermediate age-related macular degeneration (AMD) As per the deal, following successful tech evaluation, Ikarovec will lead the clinical development & commercialization of IKAR-003, with the proposed transaction for its intermediate AMD potential expected…

ByRidhi RastogiJanuary 6, 2026

INSIGHTS+

Insights+: The US FDA New Drug Approvals in August 2023

Shots: The US FDA approved 10 NDAs and 3 BLA in August 2023, leading to treatments for patients and advances in the healthcare industry. The CDER and CBER approved 89 novel products in 2023 In August 2023, the major highlights drugs were Zurzuvae (zuranolone) approval for women with postpartum depression and Veopoz (pozelimab-bbfg) for children…

BySenior EditorSeptember 20, 2023

INSIGHTS+

Disease of the Month: Age-Related Macular Degeneration

Introduction: AMD, an eye disease that can cause of loss of eyesight/blur vision mostly in people ≥50 years of age and it is the leading cause of visual impairment worldwide. It occurs when the part of the retina (macula) is damaged. Patients lose their central vision and cannot see fine details The three stages of…

BySenior EditorFebruary 9, 2023

VIEWPOINTS

Dr. Jeff Cleland, CEO & President at Ashvattha Therapeutics Shares his Views From First Patient Enrolled for the Treatment of AMD and DME

Shots: Jeff spoke about the first patient enrolled in a P-II study of D-4517.2 for the treatment of wet AMD and DME Jeff also talked about Ashvatta’s Hydroxyl Dendrimer Platform and how this technology is beneficial to treat AMD and DME The interview gives a profound understanding of how Ashvattha is developing hydroxyl dendrimer therapeutics…

BySenior EditorJanuary 3, 2023

Ikarovec Secures Global Option to VectorBuilder’s Intravitreal Capsid Technology

Disease of the Month: Age-Related Macular Degeneration

Dr. Jeff Cleland, CEO & President at Ashvattha Therapeutics Shares his Views From First Patient Enrolled for the Treatment of AMD and DME

Contact US

FOLLOW US